The Asp299 Gly toll-like receptor 4 polymorphism in advanced aortic atherosclerosis

Netherlands Journal of Medicine

Volumn 65, Issue 6, 2007, Pages 203-207

  Hommels, M J ^a   Kroon, A A ^a   Netea, M G ^b   de Leeuw, P W ^a   Bruggeman, C A ^a   Leiner, T ^a   Koster, D A ^a   Stalenhoef, A F H ^b   van der Ven, A J A M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiography; Atherosclerosis; Hypertension; Toll like receptor

Indexed keywords

ASPARTIC ACID; CHOLESTEROL; CREATININE; DNA; GLUCOSE; GLYCINE; TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE COURSE; DNA ISOLATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HYPERTENSION; INCIDENCE; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; RENAL ARTERY; RENOVASCULAR DISEASE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE DISEASE; AMINO ACID SUBSTITUTION; AORTA DISEASE; ARTERIOSCLEROSIS; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK; RISK FACTOR;

ACUTE DISEASE; AMINO ACID SUBSTITUTION; ANGIOGRAPHY, DIGITAL SUBTRACTION; AORTA, ABDOMINAL; AORTIC DISEASES; ARTERIOSCLEROSIS; CORONARY ANGIOGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; RISK; RISK FACTORS; TOLL-LIKE RECEPTOR 4; VARIATION (GENETICS);

EID: 34347270520     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Schwartz DA. The genetics of innate immunity. Chest 2002;121(3 suppl):562-8.
2. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005;5:156-64.
3. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-61.
4. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282(5396):2085-8.
5. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25(2):187-91.
6. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167(5):2887-94.
7. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276(13):10229-33.
8. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164(2):558-61.
9. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195(1):99-111.
10. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104(25):3103-8.
11. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278(3):1561-8.
12. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;107(19):2416-21.
13. Schwartz DA, Cook DN. Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 2005;41 Suppl 7:S403-7.
14. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347(3):185-92.
15. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23(12):e61-4.
16. Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004;25(16):1447-53.
17. Hernesniemi J, Lehtimaki T, Rontu R, et al. Toll-like receptor 4 polymorphism is associated with coronary stenosis but not with the occurrence of acute or old myocardial infarctions. Scand J Clin Lab Invest 2006;66(8):667-75.
18. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005;15(1):15-21.
19. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006;27(21):2524-9.
20. Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004;148(6):1034-40.
21. Yang JA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003;170(1):187-90.
22. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36(1):154-7.
23. Netea MG, Hijmans A, van Wissen S, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest 2004;34(2):94-9.
24. Norata GD, Garlaschelli K, Ongari M, et al. Effect ofthe Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 2005;258(1):21-7.
25. Beutler B, Beutler E. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347(24):1978-80; author's reply p. 80.
26. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344(6):431-42.
27. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998;129(9):705-11.
28. Anderson GH, Jr, Blakeman N, Streeten DH. Prediction of renovascular hypertension. Comparison of clinical diagnostic indices. Am J Hypertens 1988;1(3 Pt 1):301-4.
29. Detection, evaluation, and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension. Arch Intern Med 1987;147(5):820-9.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
31. Sham P. Arnolds applications of statistics. London: Arnold; 1998.
32. von Aulock S, Schroder NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003;188(6):938-43.
33. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;197(12):1787-91.
34. van der Graaf C, Kullberg BJ, Joosten L, et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005;30(5):264-8.
35. Schmitt C, Humeny A, Becker CM, Brune K, Pahl A. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002;48(10):1661-7.
36. Kiechl S, Wiedermann CJ, Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med 2003;35(3):164-71.